JP2010518816A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010518816A5 JP2010518816A5 JP2009549472A JP2009549472A JP2010518816A5 JP 2010518816 A5 JP2010518816 A5 JP 2010518816A5 JP 2009549472 A JP2009549472 A JP 2009549472A JP 2009549472 A JP2009549472 A JP 2009549472A JP 2010518816 A5 JP2010518816 A5 JP 2010518816A5
- Authority
- JP
- Japan
- Prior art keywords
- herpes simplex
- simplex virus
- nucleic acid
- polypeptide
- ing4
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101001001418 Homo sapiens Inhibitor of growth protein 4 Proteins 0.000 claims description 26
- 102100035677 Inhibitor of growth protein 4 Human genes 0.000 claims description 24
- 229920001184 polypeptide Polymers 0.000 claims description 20
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 20
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 20
- 241000700584 Simplexvirus Species 0.000 claims 27
- 150000007523 nucleic acids Chemical group 0.000 claims 14
- 210000004027 cell Anatomy 0.000 claims 10
- 108020004707 nucleic acids Proteins 0.000 claims 8
- 102000039446 nucleic acids Human genes 0.000 claims 8
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 6
- 101150076998 ICP34.5 gene Proteins 0.000 claims 4
- 238000000338 in vitro Methods 0.000 claims 4
- 231100000501 nonneurotoxic Toxicity 0.000 claims 4
- 230000010076 replication Effects 0.000 claims 3
- 101100508081 Human herpesvirus 1 (strain 17) ICP34.5 gene Proteins 0.000 claims 2
- 101150027249 RL1 gene Proteins 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 239000002773 nucleotide Substances 0.000 claims 2
- 125000003729 nucleotide group Chemical group 0.000 claims 2
- 238000002560 therapeutic procedure Methods 0.000 claims 2
- 208000009889 Herpes Simplex Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000000174 oncolytic effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 230000003362 replicative effect Effects 0.000 claims 1
- 230000035897 transcription Effects 0.000 claims 1
- 238000013518 transcription Methods 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 241000283690 Bos taurus Species 0.000 description 2
- 241000252212 Danio rerio Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000044392 human ING4 Human genes 0.000 description 2
- -1 BC007781 Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 241000282553 Macaca Species 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 241000289581 Macropus sp. Species 0.000 description 1
- 101100233089 Mus musculus Ing4 gene Proteins 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0703066.1 | 2007-02-16 | ||
| GB0703066A GB0703066D0 (en) | 2007-02-16 | 2007-02-16 | Viruses |
| US91686207P | 2007-05-09 | 2007-05-09 | |
| US60/916,862 | 2007-05-09 | ||
| PCT/GB2008/000527 WO2008099189A2 (en) | 2007-02-16 | 2008-02-15 | Herpes simplex viruses and methods of viral replication |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010518816A JP2010518816A (ja) | 2010-06-03 |
| JP2010518816A5 true JP2010518816A5 (enExample) | 2011-04-07 |
| JP5442452B2 JP5442452B2 (ja) | 2014-03-12 |
Family
ID=39271813
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009549472A Expired - Fee Related JP5442452B2 (ja) | 2007-02-16 | 2008-02-15 | 単純ヘルペスウイルスおよびウイルス複製法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US8163292B2 (enExample) |
| EP (1) | EP2114420B1 (enExample) |
| JP (1) | JP5442452B2 (enExample) |
| GB (1) | GB2446721B (enExample) |
| WO (1) | WO2008099189A2 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9415320D0 (en) | 1994-07-29 | 1994-09-21 | Medical Res Council | Cancer treatment |
| US7897146B2 (en) | 2003-11-17 | 2011-03-01 | Crusade Laboratories Limited | Treatment using herpes simplex virus |
| JP2007511216A (ja) | 2003-11-17 | 2007-05-10 | クルセイド ラボラトリーズ リミテッド | 変異ウイルス |
| JP5442452B2 (ja) * | 2007-02-16 | 2014-03-12 | ウイルツ・バイオロジクス・リミテッド | 単純ヘルペスウイルスおよびウイルス複製法 |
| EP2764119A2 (en) | 2011-10-05 | 2014-08-13 | Genelux Corporation | Method for detecting replication or colonization of a biological therapeutic |
| WO2013138522A2 (en) | 2012-03-16 | 2013-09-19 | Genelux Corporation | Methods for assessing effectiveness and monitoring oncolytic virus treatment |
| WO2013158265A1 (en) | 2012-04-20 | 2013-10-24 | Genelux Corporation | Imaging methods for oncolytic virus therapy |
| EP2662117A1 (en) * | 2012-05-11 | 2013-11-13 | Virttu Biologics Limited | Herpes Simplex Virus for the treatment of liver cancer |
| WO2014055960A1 (en) | 2012-10-05 | 2014-04-10 | Genelux Corporation | Energy absorbing-based diagnostic and therapeutic methods employing nucleic acid molecules encoding chromophore-producing enzymes |
| WO2015103438A2 (en) | 2014-01-02 | 2015-07-09 | Genelux Corporation | Oncolytic virus adjunct therapy with agents that increase virus infectivity |
| AU2015332533B2 (en) | 2014-10-14 | 2018-08-30 | Halozyme, Inc. | Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same |
| AU2017248830B2 (en) | 2016-04-15 | 2023-03-09 | Alpine Immune Sciences, Inc. | CD80 variant immunomodulatory proteins and uses thereof |
| SG11201808457PA (en) | 2016-04-15 | 2018-10-30 | Alpine Immune Sciences Inc | Icos ligand variant immunomodulatory proteins and uses thereof |
| WO2018022945A1 (en) | 2016-07-28 | 2018-02-01 | Alpine Immune Sciences, Inc. | Cd112 variant immunomodulatory proteins and uses thereof |
| EP3491013A1 (en) | 2016-07-28 | 2019-06-05 | Alpine Immune Sciences, Inc. | Cd155 variant immunomodulatory proteins and uses thereof |
| US11471488B2 (en) | 2016-07-28 | 2022-10-18 | Alpine Immune Sciences, Inc. | CD155 variant immunomodulatory proteins and uses thereof |
| EP3872180A1 (en) | 2016-10-20 | 2021-09-01 | Alpine Immune Sciences, Inc. | Secretable variant immunomodulatory proteins and engineered cell therapy |
| AU2018219895C1 (en) | 2017-02-09 | 2024-10-03 | Indapta Therapeutics, Inc. | Engineered Natural Killer (NK) cells and compositions and methods thereof |
| JP2020511144A (ja) | 2017-03-16 | 2020-04-16 | アルパイン イミューン サイエンシズ インコーポレイテッド | Ｐｄ−ｌ２バリアント免疫調節タンパク質及びその使用 |
| MX2019010887A (es) | 2017-03-16 | 2019-10-15 | Alpine Immune Sciences Inc | Proteinas inmunomoduladoras de cb80 variante y usos de estas. |
| FI3596116T3 (fi) | 2017-03-16 | 2023-11-09 | Alpine Immune Sciences Inc | Immunomodulatorisia pd-l1-varianttiproteiineja ja niiden käyttöjä |
| JP7282760B2 (ja) | 2017-10-18 | 2023-05-29 | アルパイン イミューン サイエンシズ インコーポレイテッド | バリアントｉｃｏｓリガンド免疫調節タンパク質ならびに関連する組成物および方法 |
| SG11202006148UA (en) | 2018-01-03 | 2020-07-29 | Alpine Immune Sciences Inc | Multi-domain immunomodulatory proteins and methods of use thereof |
| KR102662837B1 (ko) | 2018-06-04 | 2024-05-03 | 카리디 바이오테라퓨틱스, 인크. | 바이러스 치료법의 강화를 위한 세포-기반 비히클 |
| WO2019241758A1 (en) | 2018-06-15 | 2019-12-19 | Alpine Immune Sciences, Inc. | Pd-1 variant immunomodulatory proteins and uses thereof |
| WO2020047161A2 (en) | 2018-08-28 | 2020-03-05 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
| CA3116192C (en) | 2018-11-06 | 2025-09-23 | Calidi Biotherapeutics (Nevada), Inc. | IMPROVED SYSTEMS FOR CELL-MEDIATED ONCOLYTIC VIRAL THERAPY |
| EP3884041A2 (en) | 2018-11-21 | 2021-09-29 | Indapta Therapeutics, Inc. | Methods for expansion of natural killer (nk) cell subset and related compositions and methods |
| CN113727998A (zh) | 2018-11-30 | 2021-11-30 | 高山免疫科学股份有限公司 | Cd86变体免疫调节蛋白及其用途 |
| KR20220004959A (ko) | 2019-02-27 | 2022-01-12 | 액팀 테라퓨틱스, 인코퍼레이티드 | 종양, 종양-상주 면역 세포, 및 종양 미세환경을 콜로니화하기 위해 조작된 면역자극성 박테리아 |
| US20230118087A1 (en) * | 2019-09-03 | 2023-04-20 | Krystal Biotech, Inc. | Compositions and methods for the treatment of congenital ichthyoses |
| KR20230088306A (ko) | 2020-04-22 | 2023-06-19 | 인답타 세라뷰틱스 인코포레이티드 | 자연 살해(ｎｋ) 세포 조성물 및 이를 생성하는 방법 |
| WO2022147481A1 (en) | 2020-12-30 | 2022-07-07 | Ansun Biopharma Inc. | Combination therapy of an oncolytic virus delivering a foreign antigen and an engineered immune cell expressing a chimeric receptor targeting the foreign antigen |
| WO2026076297A1 (en) * | 2024-10-03 | 2026-04-09 | Candel Therapeutics, Inc. | Compositions and methods for treating melanoma using an oncolytic virus |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2347836A1 (en) * | 1998-10-20 | 2000-04-27 | Incyte Pharmaceuticals, Inc. | Proliferation and apoptosis related proteins |
| CN1183250C (zh) * | 2000-12-01 | 2005-01-05 | 卫健生物科技有限公司 | 高效表达肿瘤血管生成抑制因子的肿瘤细胞内特异性增殖的病毒及其构建方法 |
| GB0317511D0 (en) * | 2003-07-25 | 2003-08-27 | Biovex Ltd | Viral vectors |
| JP2007511216A (ja) * | 2003-11-17 | 2007-05-10 | クルセイド ラボラトリーズ リミテッド | 変異ウイルス |
| GB0326798D0 (en) * | 2003-11-17 | 2003-12-24 | Crusade Lab Ltd | Methods for generating mutant virus |
| CN1714871A (zh) * | 2004-06-29 | 2006-01-04 | 上海人类基因组研究中心 | 人类ing4基因作为化疗药物增敏剂的用途 |
| JP5442452B2 (ja) * | 2007-02-16 | 2014-03-12 | ウイルツ・バイオロジクス・リミテッド | 単純ヘルペスウイルスおよびウイルス複製法 |
| CN101058809B (zh) * | 2007-04-02 | 2010-09-08 | 苏州大学 | 人源化改造的鼠ing4基因及其腺病毒表达载体在制备治疗肺癌的药物中的应用 |
-
2008
- 2008-02-15 JP JP2009549472A patent/JP5442452B2/ja not_active Expired - Fee Related
- 2008-02-15 WO PCT/GB2008/000527 patent/WO2008099189A2/en not_active Ceased
- 2008-02-15 EP EP08709418.1A patent/EP2114420B1/en not_active Not-in-force
- 2008-02-15 GB GB0802868A patent/GB2446721B/en not_active Expired - Fee Related
- 2008-02-15 US US12/527,380 patent/US8163292B2/en not_active Expired - Fee Related
-
2012
- 2012-03-12 US US13/417,708 patent/US8969063B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | Cynoglossus semilaevis ISG15: a secreted cytokine-like protein that stimulates antiviral immune response in a LRGG motif-dependent manner | |
| JP2021518102A5 (enExample) | ||
| JP2020515572A (ja) | 横隔膜特異的核酸調節エレメントならびにその方法および使用 | |
| JP2013535969A5 (enExample) | ||
| CN104039833A (zh) | 针对hpv的疫苗 | |
| JP2022524212A (ja) | 操作されたｍＲＮＡ配列及びその使用 | |
| Yang et al. | Systemic administration of AAV-Slc25a46 mitigates mitochondrial neuropathy in Slc25a46−/− mice | |
| CA3121528A1 (en) | Anellosomes and methods of use | |
| JP6949867B2 (ja) | 神経の過剰興奮を治療するための方法および組成物 | |
| Mandel et al. | Viral vectors for in vivo gene transfer in Parkinson's disease: properties and clinical grade production | |
| Zhao et al. | The regulation of antiviral activity of interferon epsilon | |
| Li et al. | Cherry valley ducks mitochondrial antiviral-signaling protein-mediated signaling pathway and antiviral activity research | |
| CN103923207B (zh) | 一种fgf-21突变体蛋白的制备及其在治疗非酒精性脂肪肝中的应用 | |
| Cheng et al. | Cloning, expression and functional analysis of the duck Toll-like receptor 5 (TLR5) gene | |
| Matsumoto et al. | Amberjack Seriola dumerili interleukin-10 negatively suppresses host cell-mediated immunity | |
| Santos et al. | Teleostean IL11b exhibits complementing function to IL11a and expansive involvement in antibacterial and antiviral responses | |
| CN102180961A (zh) | 黑青斑河鲀干扰素IFNγ2及其制备方法和应用 | |
| CN104955836A (zh) | Bpifb4蛋白的变体 | |
| Pedras-Vasconcelos et al. | Immunotherapy with CpG oligonucleotides and antibodies to TNF-α rescues neonatal mice from lethal arenavirus-induced meningoencephalitis | |
| CN105348380A (zh) | 犬成纤维细胞生长因子21及其在治疗犬内分泌疾病中的用途 | |
| Bao et al. | Transcriptome profiling of the subventricular zone and dentate gyrus in an animal model of Parkinson's disease | |
| US20240076665A1 (en) | Regulatory elements for schwann cell-specific gene expression | |
| JPWO2009013794A1 (ja) | インスリン分泌誘導剤及び膵臓β細胞増加促進剤 | |
| CN103243106B (zh) | 斜带石斑鱼干扰素IFNγ1及其制备方法和应用 | |
| JPWO2014157595A1 (ja) | 新規なポリペプチドおよびその利用 |